Unadjusted and adjusted* HRs for morbidity between 2002 and 2013 from all cancer and breast cancer in the groups given folic acid supplements in the Aberdeen folic acid supplementation trial, 1966–1967
| n | Unadjusted HR (95% CI; p value) | p For trend | Adjusted HR (95% CI; p value)* | p For trend | |
|---|---|---|---|---|---|
| All cancer morbidity | |||||
| Placebo | 134 | 1.00 | 0.46 | 1.00 | 0.88 |
| 0.2 mg folic acid | 34 | 1.06 (0.73 to 1.54; 0.76) | 1.18 (0.80 to 1.75; 0.41) | ||
| 5 mg folic acid | 27 | 0.82 (0.54 to 1.24; 0.35) | 0.90 (0.59 to 1.39; 0.65) | ||
| Breast cancer morbidity | |||||
| Placebo | 34 | 1.00 | 0.77 | 1.00 | 0.98 |
| 0.2 mg folic acid | 6 | 0.74 (0.31 to 1.76; 0.50) | 0.86 (0.35 to 2.08; 0.74) | ||
| 5 mg folic acid | 8 | 0.96 (0.45 to 2.08; 0.93) | 1.06 (0.46 to 2.44; 0.89) | ||
*Adjusted for maternal age, smoking, height, weight, social class, parity and gestational age.